Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.65 |
| ▸ | NOS3 | P29474 | 6/20 | 0.65 |
| ▸ | NOS1 | P29475 | 7/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7274937 | 0.87 | NOS2 (0.54) | NOS2NOS3NOS1GRIN2DGRIN3B | |
| SCHEMBL29739615 | 0.79 | NOS2 (0.52) | NOS2NOS3NOS1GRIN2DGRIN3B | |
| SCHEMBL3552503 | 0.79 | NOS2 (0.52) | NOS2NOS3NOS1GRIN2DGRIN3B | |
| SCHEMBL2623106 | 0.79 | NOS2 (0.63) | NOS2NOS3NOS1 | |
| SCHEMBL7049604 | 0.79 | NOS2 (1.00) | NOS2NOS3NOS1 | |
| SCHEMBL26241408 | 0.77 | NOS3 (0.45) | NOS2NOS3NOS1GRIN2DGRIN3B | |
| SCHEMBL27465346 | 0.77 | NOS3 (0.45) | NOS2NOS3NOS1GRIN2DGRIN3B | |
| SCHEMBL26241406 | 0.77 | NOS3 (0.45) | NOS2NOS3NOS1GRIN2DGRIN3B | |
| SCHEMBL5865115 | 0.77 | NOS3 (0.45) | NOS2NOS3NOS1GRIN2DGRIN3B | |
| SCHEMBL13789388 | 0.77 | NOS2 (0.61) | NOS2NOS3NOS1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-4931487-A | Chain extenders for polyurethanes | DOW CHEMICAL COMPANY | 1990-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | NOS2 3160/4885NOS3 622/4885NOS1 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.